BridgeBio Pharma Inc represents a commitment to innovative solutions and transformative therapies. Guided by a strong corporate philosophy, the company focuses on addressing unmet medical needs and improving patient outcomes. BridgeBio Pharma Inc pioneers in developing targeted medicines for genetic diseases and cancers. With their dedication to scientific excellence, they identify potential drug candidates and accelerate their development through collaborations and partnerships. By leveraging cutting-edge research and technological advancements, BridgeBio Pharma Inc aims to positively impact the lives of patients and families affected by rare genetic disorders.

BridgeBio Pharma Inc is primarily present in the United States.

BridgeBio Pharma Inc has achieved several significant milestones since its inception. The company has successfully developed a diverse pipeline of investigative compounds across multiple therapeutic areas, including genetically defined diseases and cancers. BridgeBio Pharma has also formed strategic partnerships with leading pharmaceutical companies to accelerate the development and commercialization of its promising candidates. Additionally, the company has received regulatory approvals for several of its therapeutics and has successfully advanced them into clinical trials. These milestones highlight BridgeBio Pharma's commitment to addressing unmet medical needs and advancing innovative therapies for patients around the world.

BridgeBio Pharma Inc is a leading pharmaceutical company specializing in the development and commercialization of targeted therapies for genetic diseases and cancers. Founded in 2015, BridgeBio Pharma Inc has rapidly grown into a prominent player in the biotechnology industry. The company's mission is to identify and advance transformative medicines that address the unmet needs of patients with genetically driven conditions. With its innovative pipeline of candidates, BridgeBio Pharma Inc aims to make a meaningful impact on patients' lives. By leveraging its deep expertise in genetics and drug development, the company is poised to revolutionize the treatment landscape for various rare diseases and oncology indications.

The main competitors of BridgeBio Pharma Inc in the market include companies such as Amgen Inc, Gilead Sciences Inc, Biogen Inc, and Vertex Pharmaceuticals Incorporated.

BridgeBio Pharma Inc is primarily active in the biotechnology and pharmaceutical industries.

BridgeBio Pharma Inc is a biopharmaceutical company specializing in the development and commercialization of genetic medicines. The company aims to identify and advance therapies for diseases with clear genetic causes, leveraging its deep understanding of molecular pathways and human biology. BridgeBio Pharma Inc follows a diversified business model, which includes creating subsidiary companies focused on developing treatments for specific genetic diseases. These subsidiaries collaborate with academic institutions and industry partners to expedite the development of innovative therapies. By focusing on genetically driven diseases and utilizing a collaborative approach, BridgeBio Pharma Inc strives to bring transformative treatments to patients in need.

BridgeBio Pharma의 P/E 비율은 -6.67입니다.

BridgeBio Pharma의 P/S 비율은 25.8입니다.

BridgeBio Pharma에 대한 AlleAktien 품질 점수는 4/10입니다.

예상되는 BridgeBio Pharma 매출은 184.33 백만 USD입니다.

예상되는 BridgeBio Pharma 이익은 -712.92 백만 USD입니다.

BridgeBio Pharma Inc. is a biotechnology company focused on developing drugs for rare diseases. The company was founded in 2015 and is based in Palo Alto, California. Its business model is based on identifying and developing therapy approaches for rare diseases. BridgeBio works closely with researchers, academics, and other biotech companies to develop innovative therapies. It has a strong pipeline of drug candidates in preclinical and clinical studies. Flagship products include Infigratinib for FGFR2-gene defined cholangiocarcinoma and BBP-265 for ACADVL deficiency. BridgeBio has partnerships with major pharmaceutical companies such as Pfizer and Roche. It focuses on rare diseases, taking advantage of the limited treatment options and strong need in these patient populations. The company is funded through investments from venture capital firms and public institutions. It had a successful IPO in June 2019, raising nearly $350 million for pipeline development and financing teams working on new therapies. Overall, BridgeBio's business model is centered on identifying and developing therapies for rare diseases, with a strong pipeline and partnerships in place.

BridgeBio Pharma은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

BridgeBio Pharma의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

BridgeBio Pharma의 ISIN은 US10806X1028입니다.

BridgeBio Pharma의 WKN은 A2PLX7입니다.

BridgeBio Pharma의 티커는 BBIO입니다.

지난 12개월 동안 BridgeBio Pharma은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 BridgeBio Pharma은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

BridgeBio Pharma의 현재 배당 수익률은 입니다.

BridgeBio Pharma은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

BridgeBio Pharma은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

BridgeBio Pharma은 '건강' 섹터에 속합니다.

BridgeBio Pharma의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 BridgeBio Pharma는 0 USD를 배당금으로 지급했습니다.

BridgeBio Pharma의 배당금은 USD에 지급됩니다.